Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07813481

ELderly REspiratory VIral Cohort

In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations.

Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases.

The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Influenza Viruses Adenoviridae Infections Adenovirus Coronaviridae Infections Coronavirus Coronavirus Infections DNA Virus Infections Human Metapneumovirus (hMPV) Infections Nidovirales Infections Parainfluenza Virus (PIV) RNA Virus Infections Respiratory Syncytial Virus (RSV) Rhinovirus Severe Acute Respiratory Syndrome Coronavirus 2 Virus Diseases

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 65 years or older
  • Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4.
  • Hospitalized in an Acute Medicine/Geriatrics Unit
  • Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person.
  • Affiliated to a social security scheme

Exclusion criteria

  • Refusal to participate
  • Patient deprived of liberty by a judicial or administrative decision

Treatment and study plan

Respiratory viral infection

Other

Respiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.

Primary outcomes

  1. Proportion of participants with death and/or organ decompensation at Day 180

    Time frame: From baseline Day 0 to Day 180

    Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.

Secondary outcomes

  1. Proportion of participants who died

    Time frame: From baseline Day 0 to Day 30, Day 180, Day 365

    Proportion of participants who died from any cause during follow-up.

  2. Proportion of participants with major organ decompensation

    Time frame: From baseline Day 0 to Day 30, Day 180, Day 365

    Proportion of participants experiencing major decompensation of pre-existing comorbidities, including cardiac, renal, or respiratory decompensation.

  3. Proportion of participants with unplanned hospital readmission

    Time frame: From baseline Day 0 to Day 30, Day 180, Day 365

    Proportion of participants experiencing an unplanned hospital readmission during follow-up.

  4. Proportion of participants developing a lower respiratory tract infection

    Time frame: From baseline Day 0 to Day 30

    Proportion of participants developing a lower respiratory tract infection (LRTI) following the respiratory viral infection.

  5. Change from baseline in functional dependency assessed by ADL and/or iADL scores

    Time frame: Baseline Day 0, Day 30, Day 180, Day 365

    Change in functional dependency from baseline, assessed using the Activities of Daily Living (ADL) and/or Instrumental Activities of Daily Living (iADL) scores.

  6. Change from baseline in sarcopenia risk assessed by SARC-F score

    Time frame: Baseline Day 0, Day 30, Day 180, Day 365

    Change in sarcopenia risk from baseline, assessed using the SARC-F score.

  7. Change from baseline in quality of life assessed by EQ-5D-3L

    Time frame: Baseline Day 0, Day 30, Day 180, Day 365

    Change in health-related quality of life from baseline, assessed using the EQ-5D-3L questionnaire.

  8. Number and type of bacterial and viral co-infections

    Time frame: Baseline Day 0 to D7

    Number and type of bacterial and viral co-infections diagnosed at the same time as, or within seven days following, the occurrence of the first respiratory viral infection.

  9. Change in respiratory viral load between Day 0 and Day 7

    Time frame: From Day 0 to Day 7

    Change in viral load between Day 0 and Day 7 for each respiratory virus identified in study participants.

  10. Proportion of participants with death and/or major organ decompensation at Day 30

    Time frame: From baseline Day 0 to Day 30

    Proportion of participants who died and/or experienced major organ decompensation by Day 30. This outcome will be used to assess vaccine effectiveness for vaccine-preventable respiratory viral infections.

Study contacts

Contact information is provided by the study sponsor or research team.

Giovanna Mrs MELICA, MD, PhD

CONTACT

[email protected]

01 49 81 2455

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Prognostic Role of the Human Metapneumovirus (hMPV) Compared to Other Common Respiratory Viruses in Older Inpatients: a Cohort Study

Acronym: ELREVI

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Sep 10, 2026
Registry last updated
Sep 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.